Torrent Pharmaceuticals Limited successfully concluded an NCLT convened meeting of equity shareholders on April 28, 2026, where shareholders approved the proposed scheme of amalgamation with J. B. Chemicals & Pharmaceuticals Limited. The meeting marks a significant milestone in the consolidation process between the two pharmaceutical companies.

Meeting Details and Proceedings

The NCLT convened meeting was conducted through video conferencing and other audio-visual means, commencing at 10:00 a.m. IST and concluding at 10:21 a.m. IST on April 28, 2026. Mahesh Gupta, appointed as Chairman for the NCLT convened meeting, presided over the proceedings with the requisite quorum being present.

Amalgamation Scheme Approval

The proposed scheme of amalgamation between J. B. Chemicals & Pharmaceuticals Limited (Transferor Company) and Torrent Pharmaceuticals Limited (Transferee Company) received approval from equity shareholders with the requisite majority. The approval was secured under the provisions of Section 230(6) of the Companies Act, 2013, which requires majority of equity shareholders and three-fourths in value of equity shareholders who cast their votes.

The voting process was conducted through both remote e-voting and e-voting at the meeting, ensuring compliance with the Companies Act, listing regulations, and circulars issued by the Ministry of Corporate Affairs. This dual voting mechanism provided shareholders with flexible participation options while maintaining regulatory compliance.

Regulatory Compliance and Next Steps

Torrent Pharmaceuticals has committed to disclosing the detailed results of remote e-voting and e-voting at the meeting along with the scrutinizer's report to stock exchanges separately. This disclosure will be made as required under Regulation 44(3) of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

The company communicated the meeting proceedings to both BSE Limited and National Stock Exchange of India Limited in compliance with Regulation 30 of the listing regulations. The successful approval of the amalgamation scheme represents a crucial step forward in the merger process between the two pharmaceutical entities.

Corporate Information

Torrent Pharmaceuticals Limited, incorporated with CIN L24230GJ1972PLC002126, operates from its registered office at Avirat, Thaltej Shilaj Road, Ahmedabad. The company maintains active communication channels for investor services and continues to ensure transparent disclosure of material developments to stakeholders and regulatory authorities.

Torrent Pharmaceuticals Limited has successfully completed a United States Food and Drug Administration (USFDA) inspection of its Bileshwarpura oncology facility with zero observations. The pharmaceutical company announced this significant regulatory milestone in a communication to stock exchanges on April 10, 2026.

USFDA Inspection Details

The inspection covered the company's Bileshwarpura facility, which specializes in oncology drug manufacturing. The regulatory review was conducted over a four-day period and concluded without any findings or observations from the USFDA inspectors.

Regulatory Compliance Achievement

The zero observation outcome represents a clean inspection result, indicating that the facility met all USFDA manufacturing standards and regulatory requirements. This achievement is particularly significant for an oncology facility, where stringent quality controls and manufacturing practices are essential for producing cancer treatment medications.

Corporate Disclosure

Torrent Pharmaceuticals fulfilled its disclosure obligations by informing both major Indian stock exchanges about the inspection outcome. The company submitted the notification under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparency with investors and stakeholders.

The communication was signed by Chintan M. Trivedi, Company Secretary, and formally addressed to the listing departments of both BSE Limited and National Stock Exchange of India Limited. This regulatory filing demonstrates the company's commitment to maintaining proper corporate governance and timely disclosure practices.

Manufacturing Excellence

The successful completion of the USFDA inspection with zero observations reflects the company's robust quality management systems and manufacturing capabilities at its oncology facility. Such outcomes are crucial for pharmaceutical companies seeking to maintain their market access and regulatory standing in the United States, one of the world's largest pharmaceutical markets.